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Abstract  33 
Background 34 
Non-muscle invasive bladder cancer (NMIBC) has a significant risk of recurrence despite 35 
adjuvant intravesical therapy. 36 
Objective 37 
To determine if celecoxib, a COX-2 inhibitor, reduces the risk of recurrence in NMIBC 38 
patients receiving standard treatment. 39 
Design, Setting and Participants 40 
BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III, randomised 41 
controlled trial. Patients aged 18 years with intermediate or high risk NMIBC were accrued 42 
across 51 United Kingdom centres between 1st November 2007 and 23rd July 2012.  43 
Interventions 44 
Patients were randomised (1:1) to celecoxib 200 mg twice daily or placebo for two years. 45 
Patients with intermediate risk NMIBC were recommended to receive 6 weekly mitomycin 46 
C; high risk NMIBC cases received 6 weekly Bacillus Calmette Guérin and maintenance 47 
therapy.  48 
Outcome measurements and statistical analysis 49 
The primary endpoint was time to disease recurrence. Analysis was by intention to treat.  50 
Results and limitations 51 
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A total of 472 patients were randomised (236:236). With median follow-up of 44 months 52 
(IQR: 36-57), 3-year recurrence-free rate (RFR) (95% CI) was celecoxib: 68% (61%-74%) 53 
versus placebo: 64% (57%-70%) (hazard ratio (HR) 0.82, [0.60-1.12], p=0.2). There was no 54 
difference in high (HR 0.77 [0.52-1.15], p=0.2) or intermediate risk (HR 0.90 [0.55-1.48], 55 
p=0.7) NMIBC. Subgroup analysis suggested time to recurrence was longer in pT1 NMIBC 56 
patients treated with celecoxib compared to placebo (HR: 0.53, [0.30-0.94], interaction test 57 
p=0.04). The 3-year progression rates in high risk patients were low: 10% (6.5%-17%) and 58 
9.7% (6.0%-15%) in celecoxib and placebo arms respectively. Incidence of serious 59 
cardiovascular events was higher in celecoxib (5.2%) than placebo (1.7%) (difference +3.4% 60 
[-0.3%-7.2%], p=0.07).    61 
Conclusion 62 
BOXIT did not show that celecoxib reduces the risk of recurrence in intermediate or high risk 63 
NMIBC although celecoxib was associated with delayed time to recurrence in pT1 NMIBC 64 
patients. The increased risk of cardiovascular events does not support the use of celecoxib.   65 
Patient summary 66 
Celecoxib was not shown to reduce the risk of recurrence in intermediate or high risk NMIBC 67 
although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. 68 
The increased risk of cardiovascular events does not support the use of celecoxib.   69 
 70 
Key words: bladder cancer; chemoprevention; COX-2 inhibitor; randomised trial; 71 
cardiovascular events.  72 
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1. Introduction 73 
Bladder cancer represents the 9th most common cancer with 429,000 new cases per year 74 
worldwide [1]. Over 75% of new cases are non-muscle invasive bladder cancer (NMIBC) and 75 
following tumour resection, between 28-52% of patients will develop recurrence within 5 76 
years [2]. Efforts to reduce recurrence of NMIBC include the use of intravesical 77 
chemotherapy and Bacillus Calmette Guérin (BCG) [3, 4].  78 
Cyclo-oxygenase (COX) enzyme controls a rate limiting step implicated in carcinogenesis by 79 
regulating the conversion of arachidonic acid to prostaglandin E2 (PGE2) and inhibits 80 
apoptosis by overexpressing Bcl-2 [5]. Inhibition of COX-2 results in cell cycle arrest 81 
triggering apoptosis in in vitro studies [6]. A population-based case-controlled study 82 
reported that patients taking regular NSAIDs had an a lower risk of developing bladder 83 
cancer (odds ratio 0.81, 95% CI: 0.68-0.96) compared to non- or irregular NSAID use patients 84 
[7]. Consistent with this, COX-2 is overexpressed in bladder cancer compared to normal 85 
urothelium and COX-2 expression is associated with disease recurrence and progression [8].  86 
A phase II randomised controlled trial (RCT) comparing celecoxib, a selective COX-2 87 
inhibitor, to placebo in high risk NMIBC recruited subjects who received adjuvant BCG was 88 
reported by Sabichi and colleagues [9]. It was powered to detect a large treatment effect of 89 
53% relative reduction in recurrence at 12 months but failed to show a difference [9]. 90 
Further, the study did not assess health related quality of life (HRQOL). The BOXIT study 91 
(ISRCTN84681538) sought to determine if celecoxib in combination with standard therapy is 92 
more effective in terms of reducing to the risk of disease recurrence than standard therapy 93 
alone for the treatment of intermediate or high risk NMIBC.  94 
  95 
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2. Patients and Methods 96 
2.1 Trial design  97 
BOXIT (CRUK/07/004) is a multicentre, phase III, randomised, double-blind, placebo-98 
controlled trial sponsored by the Institute of Cancer Research. It was approved by London–99 
Central Multicentre Research Ethics Committee and overseen by independent Trial Steering 100 
(TSC) and Data Monitoring Committees (IDMC).  101 
2.2 Patients  102 
All patients with primary or recurrent intermediate or high risk NMIBC according to 103 
European Association of Urology (EAU) guidelines (2002) were eligible for the trial [10]. 104 
Patients had complete transurethral resection of bladder tumour (TURBT) for 105 
histopathological staging and all pT1 disease underwent re-resection to confirm the absence 106 
of detrusor tumour invasion. Patients were 18 years old, with WHO performance status of 107 
≤2 with no upper tract transitional cell carcinoma (TCC) confirmed by imaging within the 108 
past 36 months and had not received NSAIDs (other than low dose aspirin ≤150 mg daily) or 109 
celecoxib for a minimum of two months prior to entry. Haematological and biochemical 110 
blood tests were within adequate levels.  111 
Key exclusion criteria include non-TCC NMIBC, tumour involving prostatic urethra or upper 112 
urinary tract, ≥pT2 TCC, known contraindications to NSAIDs, pregnant or lactating women, 113 
adverse reactions to sulfonamides or NSAIDs, current or long-term use of NSAIDs and oral 114 
corticosteroids, malignancy within the past 2 years, patients with known or suspected 115 
congestive heart failure (II-IV NYHA), cardiovascular disease, blood pressure of 116 
>160/100mmHg and/ or patients with diabetes requiring insulin.   117 
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2.3 Randomisation and Masking 118 
Following TURBT, treatment was allocated (1:1) using computer generated random 119 
permuted blocks of size 6, stratified by treating centre and risk group. ICR-CTSU performed 120 
the randomisation, and treatment allocation was blinded to participants and investigators. 121 
The IDMC reviewed safety and efficacy of the trial blinded to treatment allocation. A 122 
Cardiovascular Safety Committee (CVSC) was established to review unblinded cardiovascular 123 
safety data to advise in confidence the IDMC.  124 
2.4 Interventions 125 
Patients were randomised to either celecoxib 200mg twice daily or placebo for two years. It 126 
was recommended that all patients received standard of care single intravesical 40 mg in 40 127 
ml of MMC (MMC1) instillation within 24 hours following TURBT unless contraindicated. 128 
High risk patients received induction BCG (81 mg BCG, Connaught strain) comprising of 6 129 
weekly instillations, and maintenance therapy (three weekly instillations at 4, 6, 12, 18, 24, 130 
30, 36 months) was recommended. Study treatment was commenced before BCG induction 131 
in high risk patients. It was recommended that intermediate risk patients received 6 weekly 132 
instillations of 40mg MMC (MMC6). Disease recurrence was monitored by regular 133 
cystoscopies as per guidelines [3]. A centrally reviewed baseline ECG was performed to 134 
confirm eligibility, with follow-up ECGs at 12 and 24 months.  135 
2.5 Outcomes 136 
The primary endpoint was time to recurrence of bladder cancer which was defined as time 137 
from randomisation to date of confirmation of cancer recurrence. Secondary efficacy 138 
endpoints included NMIBC recurrence rate in intermediate risk patients, time to progression 139 
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to invasive disease in high risk patients, disease free survival and overall survival.  For 140 
disease-related events and survival, patients event free or alive at the time of analysis were 141 
censored at their last available assessment.  142 
Safety and tolerability of celecoxib were assessed by treatment compliance and reporting of 143 
adverse events (AE), graded according to the National Cancer Institute’s Common 144 
Terminology Criteria for Adverse Events (NCIC-CTCAE v3.0), and recoded using MedDRA 145 
(v14.0).  146 
HRQOL was assessed using the EORTC Quality of Life Questionnaire (EORTC QLQ-C30) [11] 147 
and the EORTC QLQ-BLS24 [12]. Patients completed questionnaires at baseline, 12, 24 and 148 
36 months. High risk patients also completed measures at 8 & 12 weeks and 6 months.  149 
2.6 Sample size and power 150 
Estimating a recurrence free rate at 3 years of 51% in the control arm, 206 patients per arm 151 
were required to detect a difference of 15% with 85% power and two-sided alpha of 5% 152 
(hazard ratio (HR) of 0.63). Assuming non-compliance rates of 14.5% at 12 months and 28% 153 
at 24 months and that stopping trial treatment early halves the treatment effect, a revised 154 
target sample size of 475 patients (193 events) with 5% drop out and 80% power was 155 
selected.  156 
2.7 Statistical analysis 157 
Analyses of outcomes were on an intention to treat (ITT) basis, and according to treatment 158 
received for safety and tolerability endpoints. Sensitivity analyses were performed on the 159 
per protocol (PP) population (≥12 months of study drug or earlier if due to disease 160 
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progression, drug toxicity or death). Statistical significance was defined as p-value= 0.05 and 161 
95% confidence intervals reported.  Analyses were adjusted by risk group.  162 
Time-to-event endpoints were summarised using Kaplan Meier methods. Treatments were 163 
compared by the stratified log-rank test and effect estimated by stratified Cox models. 164 
Consistency of treatment effect was assessed in subgroup analyses. Proportional hazards 165 
were tested using Schoenfield residuals.  166 
Worst CTCAE grade toxicities were summarised by treatment received. Incidence of 3 167 
grade and serious cardiovascular events were compared by Fisher’s exact test.  168 
Treatment effect on HRQOL were obtained from ANCOVA models. Only patients with paired 169 
baseline and timepoint data were analysed. A p-value of <0.01 (and related 99% confidence 170 
intervals) was deemed statistically significant to account for multiple comparisons.  171 
Analyses were based on trial data up to 31st December 2014 and performed using STATA 172 
version 13.1 and R version 3.4.1.  173 
  174 
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3. Results 175 
3.1 Patients  176 
Between 1st November 2007 and 23rd July 2012, 472 patients (236 celecoxib; 236 placebo) 177 
were recruited from 51 centres in the UK (Figure 1). Demographics and clinical 178 
characteristics were evenly matched across treatment groups (Table 1). Additional baseline 179 
cardiovascular risk factors for both groups are reported in the Supplement Table 1.  180 
A total of 177 (75%) in the celecoxib arm and 189 (80%) patients in the placebo arm took 181 
the study drug for ≥12 months, with 120 (51%) and 144 (61%) respectively completing 24 182 
months of study treatment (Table 2). In December 2013, the trial stopped for futility and 183 
given a small increased risk of cardiovascular event in patients on celecoxib, the CVSC, IDMC 184 
and TSC recommended halting recruitment of patients still on study treatment (6.8% 185 
celecoxib, 7.6% placebo). Follow-up continued until maturity of data at 3 years median 186 
follow-up. 187 
Compliance with standard of care treatments, by risk group and treatment arm are also 188 
shown in Table 2. The proportion of high risk patients receiving BCG maintenance decreased 189 
with time from 61% at month 4 (65% celecoxib; 58% placebo) to 13% at month 36 (13% 190 
celecoxib; 12% placebo). Fifteen patients in the intermediate group (12%) received full BCG6 191 
induction by physician choice. 192 
3.2 Recurrence free rate 193 
At median follow-up of 44 months (IQR: 36-57 months), 3-year recurrence free rate (RFR) 194 
(95% CI) was celecoxib: 68% (61%-74%) versus placebo: 64% (57%-70%) (hazard ratio (HR): 195 
0.82, [95% CI: 0.60-1.12], stratified log-rank p=0.2) (Figure 2A). When stratified by disease 196 
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risk, 3-year RFR was celecoxib: 75% (67%-81%) versus placebo: 68% (60%-74%) (HR: 0.77 197 
[0.52-1.15], log-rank p=0.2) for high risk patients (Figure 2B) and 52% (40%-64%) versus 50% 198 
(35%-63%) (HR: 0.90 [0.55-1.48], log-rank p=0.7) for intermediate risk patients (Figure 2B). 199 
Exploratory subgroup analyses of the primary endpoint are shown in Figure 3. Time to 200 
recurrence was longer in pT1 NMIBC patients in the celecoxib arm compared to placebo 201 
(HR: 0.53, [95% CI: 0.30-0.94]); this effect was not seen in pTa patients (interaction p= 0.04). 202 
Sensitivity analyses of the primary endpoint and disease free survival yielded similar results 203 
(Supplement Figures 1-3).  204 
3.3 Progression rate and overall survival  205 
The 3-year rate of progression to invasive disease in high risk patients was low in both 206 
groups: 10% (6.5%-17%) celecoxib versus 9.7% (6.0%-15%) placebo (log-rank p=0.8) 207 
(Supplement Figure 4). Overall, there were 26 deaths in the celecoxib arm, and 21 in the 208 
placebo arm. Deaths were due to bladder cancer (19), other malignancies (14), respiratory 209 
causes (6), cardiovascular causes (3) or other (5).  At 3 years, the overall survival in the 210 
celecoxib arm was 92% (95% CI: 87-95) while in the placebo arm was 94% (90%, 97%) (HR: 211 
1.21, [0.68-2.15], stratified log-rank p=0.5) (Supplement Figure 5).  212 
3.4 Safety and tolerability  213 
Worst CTC grade adverse events at any time are presented in Table 3. A total of 145 (32%) 214 
patients (30% celecoxib versus 33% placebo) suffered grade 3-4 toxicity (p= 0.6). Only in 70 215 
patients (15%) serious adverse events were reported with no differences between groups 216 
(celecoxib 16%, placebo 14%, p=0.5). Incidence of CV events reported as serious while on 217 
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treatment was higher on celecoxib (5.2%) than placebo (1.7%) (absolute difference 3.4% 218 
[95% CI: -0.3%-7.2%], p=0.07) (Supplement Table 2). 219 
3.5 HRQOL 220 
There was no significant difference in HRQOL assessed by QLQ-C30 and QLQ-NIMBC24 221 
between treatments over the 36-month follow-up (Supplement Tables 3-4). At 6 months, 222 
QLQ-C30 global health score was significantly worse than baseline in the celecoxib group 223 
but not in the placebo group, although differences between groups were not statistically 224 
significant.  This deterioration in QL persisted at 24 months.  225 
  226 
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4. Discussion  227 
The BOXIT trial did not show a difference in time to recurrence between the two treatment 228 
arms. Exploratory subgroup analysis suggested time to recurrence was significantly longer in 229 
pT1 NMIBC in the celecoxib arm compared to placebo. Cardiac events were more common 230 
with celecoxib. Strengths of the study include its size and the use of patient reported quality 231 
of life measures. 232 
Oral secondary prevention agents have been proposed in bladder cancer [13]. Sixty-four 233 
NMIBC patients receiving intravesical BCG were randomised to receive vitamins in the 234 
recommended daily allowance (RDA) or RDA multivitamins plus megadose vitamins and 235 
showed a lower 5-year recurrence free survival favouring patients treated with megadose 236 
vitamins [13]. The results of this study have not been validated and to our knowledge, BOXIT 237 
is the only phase III trial to test an oral agent in NMIBC.  238 
Despite data supporting a role of COX-2 inhibition in bladder cancer, our results do not 239 
support celecoxib as an effective chemopreventative agent for intermediate and high risk 240 
NMIBC. Similar findings were reported in a previous RCT on high risk patients [9]. There was 241 
no duration dose response as evident in the PP analysis. The results do show a significant 242 
benefit in cases with pT1 disease and although not tested in the BOXIT study, studies 243 
demonstrate a clear correlation between the expression of COX-2 and tumour stage [14].  244 
Targeting COX-2 inhibition in patients with high risk invasive (pT1) disease although 245 
attractive for secondary prevention cannot be recommended because of CV toxicity. Pooled 246 
analysis of 6 RCTs report that cardiovascular risk attributed to celecoxib is dependent on 247 
dose and baseline cardiovascular risk [15]. The higher cardiovascular event rate in this study 248 
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compared to others may reflect the fact that bladder cancer patients are often older, 249 
smokers and have had previous exposure to environmental hazards compared to the 250 
general population despite excluding patients with a history of cardiovascular disease.  251 
Whilst selective inhibition of COX-2 was initially thought to be advantageous due to a 252 
reduced risk of gastrointestinal ulceration it is apparent that COX-2 plays an important role 253 
in the vasculature leading to reduced tendency towards atherothrombosis [16]. However, 254 
since many acute coronary events occur in people without a previous history of 255 
cardiovascular disease, it is not possible to predict a low risk group for whom prolonged 256 
COX-2 therapy would be appropriate.   257 
In BOXIT, celecoxib was commenced prior to the start of BCG therapy. COX-2 induces PGE2 258 
to alter tumour cytokine microenvironment and dendritic cell antigen presentation [17]. In 259 
the preclinical setting, BCG activates dendritic cells resulting in a mixed cytokine response 260 
and COX-2 inhibition suppressed PGE2 levels, polarising dendritic cells towards an anti-261 
tumour Th1 response [18, 19]. Altering the cytokine response to BCG therapy with COX-2 262 
inhibition represents an attractive area for future research given the interest in check-point 263 
inhibitors in the NMIBC setting [20].  264 
There is a paucity of HRQOL patient reported outcomes in NMIBC. In one other RCT of 120 265 
patients, Gontero and colleagues reported a decline in global health following BCG induction 266 
therapy which improved to near baseline levels at 12 months [21].  Further exploration of 267 
HRQOL patterns and changes over time in BOXIT is planned. 268 
The results from BOXIT may point to an alternative strategy. A study of patients with Lynch 269 
syndrome randomised to either aspirin or placebo showed a risk reduction of developing 270 
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colorectal carcinoma in patients with >2 years of aspirin therapy [22]. Furthermore the 271 
benefit of aspirin is greatest in colorectal cancers which overexpress COX-2 (RR: 0.64; 95% CI 272 
0.52-0.8) but not in tumours with a low or absent COX-2 expression [23]. It will be important 273 
to understand whether non-selective COX-2 agents such as aspirin is an effective 274 
chemoprevention option in high COX-2 expressing bladder cancers. 275 
Limitations include a low uptake of patients treated with MMC6 and induction and 276 
maintenance BCG in intermediate and high risk patients respectively despite 277 
recommendation. This was not mandatory to minimise any differences in local practice to 278 
enhance patient recruitment. Further, baseline COX-2 expression was not determined in this 279 
trial. It is possible that selecting only patients overexpressing COX-2 may benefit from COX-2 280 
inhibition. 281 
5. Conclusions 282 
BOXIT suggest that COX-2 inhibition did not reduce recurrence risk in intermediate and high 283 
risk NMIBC, although time to recurrence was significantly longer in pT1 patients. While 284 
cardiovascular risk precludes the use of celecoxib for secondary prevention, international 285 
consensus supports the use of aspirin due to its efficacy as well as safety profile [24]. 286 
Ongoing trials such as  Add-Aspirin (NCT02804815), a prospective RCT investigating the role 287 
of aspirin in secondary prevention of breast, colorectal, stomach/ oesophagus and prostate 288 
cancer will help inform the development of novel trials in NMIBC. 289 
290 
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Figure legends 329 
Figure 1: Trial profile - CONSORT diagram 330 
 331 
Figure 2: Kaplan- Meier estimates of recurrence-free rates (RFR) for (A) all patients (ITT 332 
population) and in (B) High Risk patients (left) and Intermediate Risk patients (right).  333 
HR: Hazard Ratio; CI: confidence interval; abs. diff: absolute difference; strat: stratified 334 
 335 
Figure 3: Subgroup analysis: hazard ratios for recurrence-free rate (RFR) by tumour 336 
characteristics  337 
 338 
 339 
  340 
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Tables 341 
Table 1: Baseline demographics and clinical characteristics by randomised group 342 
  Celecoxib Placebo Total 
  N=236 N=236 N=472 
  N % N % N % 
Risk group             
High risk 167 71 179 76 346 73 
Intermediate risk 69 29 57 24 126 27 
Gender     
  
    
Male 188 80 186 79 374 79 
Age N=236 N=236 N=472 
Median (Q1-Q3) 66 (60-73) 68 (63-73) 67 (61-73) 
Smoking status    
Current 42 18 27 11 69 15 
Never 70 30 75 32 145 31 
Previous 122 52 130 55 252 53 
 Missing 2 0.8 4 1.7 6 1.3 
Hypertension (Systolic 140 and /or Diastolic90 )       
Yes 134 57 131 56 265 56 
No 95 40 101 43 196 42 
 Missing 7 3.0 4 1.7 11 2.3 
Diabetes       
Yes 23 9.7 19 8.1 42 8.9 
No 213 90 216 92 429 91 
 Missing 0 0.0 1 0.4 1 0.2 
Histological stage at baseline             
Ta 113 48 96 41 209 44 
T1 83 35 95 40 178 38 
Tis 24 10 28 12 52 11 
Ta/Tis 5 2.1 10 4.2 15 3.2 
T1/Tis 11 4.7 7 3.0 18 3.8 
Histological grade at baseline             
G1 14 5.9 14 5.9 28 5.9 
G2 93 39 73 31 166 35 
G3 112 48 126 53 238 50 
Unknown 13 5.5 15 6.4 28 5.9 
Missing 4 1.7 8 3.4 12 2.5 
Number of tumours at baseline*     
  
    
<3 156 66 156 66 312 66 
>=3 76 32 71 30 147 31 
Missing 4 1.7 9 3.8 13 2.8 
Tumour size at baseline*             
<3cm 75 32 74 31 149 32  
>=3cm 94 40 94 40 188 40 
Not known 67 28 68 29 135 28 
Previous recurrence in the last 2 years             
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No 165 70 166 70 331 70 
Yes 69 29 67 28 136 29 
Not known 2 0.8 3 1.3 5 1.1 
Q1= First quartile (25% percentile), Q3=Third quartile (75% percentile)  
*Numbers from histological diagnosis used where available. If not available, numbers from visual diagnosis 
used. When tumour size reported “Estimated/assumed >=3cm (n=45)”, included in >=3cm category.  
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Table 2: Compliance with trial and standard of care treatments, by risk group and treatment arm 345 
  High risk (N=346) Intermediate risk (N=126) 
  Celecoxib Placebo   Celecoxib Placebo   
  N % N % p-value N % N % p-value 
N patients 167 100 179 100   69 100 57 100   
Compliance with trial treatment                     
Completed as planned (24 months) 76 46 102 57 0.03 44 64 42 74 0.2 
Reasons for non-compliance:           
Disease progression 21 13 25 14 
0.1* 
3 4.3 1 1.7 
0.6* 
AE/tolerability 26 16 16 8.9 10 15 4 7.0 
Loss to follow-up 0 0 0 0 0 0.0 1 1.7 
Patient/clinician decision  20 12 17 9.5 3 4.3 4 7.0 
Early cessation IMP Dec 2013 12 7.2 16 8.9 4 5.8 2 3.5 
Other 12 7.2 3 1.7 5 7.3 3 5.3 
           
Completed at least 12 months of treatment 118 71 139 78 0.1 59 86 50 88 0.7 
MMC1            
MMC1 given 89 53 98 55 0.8 37 54 33 58 0.6 
MMC6 
not applicable 
          
Full MMC6 received 28 41 32 56  0.08 
BCG induction                     
Full BCG6 induction received 139 83 144 81 0.5 10 15 5 8.8  0.3 
BCG (overall)                     
None 12 7.2 13 7.3 0.9 59 86 52 91 0.6 
Only Induction 19 11 23 13   0 0 0 0   
1-3 BCG maintenance courses 74 44 74 41   4 5.8 2 3.5   
4-7 BCG maintenance courses 62 37 69 39   6 8.7 3 5.3   
MMC1= Single instillation post ingle instillation of mitomycin C post transurethral resection; MM6= Maintenance 346 
mitomycin C; BCG= Bacillus Calmette Guérin (BCG); BCG6=BCG induction  347 
*Chi2 test p-value on non-compliant pts only.  348 
  349 
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Table 3:  Frequency of adverse events by randomised group 350 
     Celecoxib N=228  Placebo N=228 Total N=456 
    N % N % N % 
Worst 
CTCAE 
grade 
overall 
0 24 11 29 13 53 12 
1 41 18 43 19 84 18 
2 90 40 76 33 166 36 
3 55 24 67 29 122 27 
4 14 6.1 9 3.9 23 5.0 
Ungraded 4 1.8 4 1.8 8 1.8 
% G3-4 69 30 76 33 145 32 
Grade 3-4 toxicities (>1% in either arm): 
Abdominal pain 6 2.6 5 2.2 11 2.4 
Alveolitis allergic 3 1.3 0 0.0 3 0.7 
Arthralgia 4 1.8 2 0.9 6 1.3 
Back pain 3 1.3 2 0.9 5 1.1 
Chills 3 1.3 0 0.0 3 0.7 
Deep vein thrombosis* 0 0.0 7 3.1 7 1.5 
Dyspepsia 5 2.2 4 1.8 9 2.0 
Dyspnoea 0 0.0 4 1.8 4 0.9 
Dysuria 3 1.3 7 3.1 10 2.2 
Fatigue 4 1.8 4 1.8 8 1.8 
Haematuria 2 0.9 3 1.3 5 1.1 
Hypertension* 9 3.9 1 0.4 10 2.2 
Insomnia 6 2.6 8 3.5 14 3.1 
Micturition urgency 2 0.9 6 2.6 8 1.8 
Pelvic pain 2 0.9 3 1.3 5 1.1 
Prostatitis* 5 2.2 0 0.0 5 1.1 
Rash 0 0.0 4 1.8 4 0.9 
Tinnitus 4 1.8 0 0.0 4 0.9 
Upper respiratory tract 
infection 
4 1.8 4 1.8 8 1.8 
Urinary frequency* 6 2.6 17 7.5 23 5.0 
Urosepsis 3 1.3 1 0.4 4 0.9 
Reported on n=456 patients with at least 1 toxicity form completed. Groups compared by: 2-sided Fisher’s 
exact test comparing number with G3-4, except for worst grade overall with Χ2 test for trend. All p-values 
>0.1 except for *Deep vein thrombosis (p=0.02) , hypertension (p=0.02), prostatitis (p=0.06) and urinary 
frequency (p=0.03). 
CTCAE= National Cancer Institute’s Common Terminology Criteria for Adverse Events v3.0 
 351 
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Figure 3
Take home message  
 
Celecoxib did not reduce the overall risk of recurrence in intermediate or high risk non-muscle 
invasive bladder cancer. Sub-group analysis report that time to recurrence was significantly longer in 
pT1 patients treated with celecoxib although cardiovascular events were higher.  
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